Waxman queries FDA on Medtronic recall
This article was originally published in The Gray Sheet
House Committee on Oversight and Government Reform Chair Henry Waxman, D-Calif., requests information on FDA's oversight of Medtronic's Sprint Fidelis defibrillator leads in an Oct. 22 letter to the agency. Medtronic recalled the leads Oct. 15 due to a propensity for fractures that has been linked to patient deaths (1"The Gray Sheet" Oct. 22, 2007, p. 3). Noting what is "apparently a serious shortcoming in the agency's approval process for these devices," Waxman asks FDA why Medtronic was not required to submit clinical data to support the leads' safety and efficacy, what information Medtronic had provided about the fracture problem and how FDA responded, and whether the agency had created new policies for the oversight of defibrillators. Sen. Chuck Grassley, R-Iowa, sent FDA a similar letter Oct. 16
You may also be interested in...
The House Committee on Oversight and Government Reform is requesting information on the off-label use and marketing of drug-eluting stents
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.